Minerva Neurosciences, Inc (NERV) – What Are Analysts Saying About This Stock?

Shares of Minerva Neurosciences, Inc (NASDAQ:NERV – Get Free Report) have been assigned an average rating of “Hold” from the four ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $10.33.

NERV has been the topic of several recent analyst reports. Zacks Research upgraded shares of Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Jefferies Financial Group upgraded shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and upped their price target for the company from $7.50 to $10.00 in a report on Friday, August 14th. Wall Street Zen cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, September 21st.

Check Out Our Latest Stock Report on NERV

Hedge Funds Weigh In On Minerva Neurosciences

Several large investors have recently made changes to their positions in NERV. OMERS ADMINISTRATION Corp bought a new stake in Minerva Neurosciences during the 1st quarter valued at approximately $62,000. Bank of America Corp DE lifted its holdings in shares of Minerva Neurosciences by 78,272.5% during the first quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 39,919 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Minerva Neurosciences during the second quarter worth approximately $419,000. Goldman Sachs Group Inc. lifted its holdings in shares of Minerva Neurosciences by 19.8% during the third quarter. Goldman Sachs Group Inc. now owns 172,461 shares of the biopharmaceutical company’s stock worth $578,000 after buying an additional 28,507 shares during the last quarter. Finally, DV Trading LLC acquired a new position in shares of Minerva Neurosciences during the first quarter worth approximately $5,358,000. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Stock Performance

NERV opened at $2.00 on Friday. The firm has a market cap of $99.66 million, a P/E ratio of -0.07 and a beta of 0.09. The business has a 50 day moving average price of $2.80 and a 200 day moving average price of $4.73. Minerva Neurosciences has a twelve month low of $1.96 and a twelve month high of $8.80.

Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.14) by ($1.46). As a group, analysts anticipate that Minerva Neurosciences will post -0.70 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

(Get Free Report)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. It focuses on developing treatments for central nervous system disorders and does not have marketed products. The company’s principal drug candidate has been roluperidone, an oral medicine studied for negative symptoms of schizophrenia. The candidate remains investigational; its development has included clinical trials and regulatory review in the United States. Minerva’s earlier research pipeline has also included MIN-301, a biologic candidate studied for Parkinson’s disease.

See Also

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.